Current therapy of the pemphigus group

Michael Kasperkiewicz*, Enno Schmidt, Detlef Zillikens

*Corresponding author for this work
50 Citations (Scopus)


Treatment of pemphigus patients is still challenging and, in some cases, conventional therapy with systemic corticosteroids in combination with adjuvant corticosteroid-sparing immunosuppressive drugs is not sufficient to induce clinical remission. More recently, high-dose intravenous immunoglobulins, immunoadsorption, and the monoclonal anti-CD20 antibody, rituximab, have been established as additional successful therapeutic options. This contribution covers both conventional therapies and most current treatment strategies for pemphigus.

Original languageEnglish
JournalClinics in Dermatology
Issue number1
Pages (from-to)84-94
Number of pages11
Publication statusPublished - 01.01.2012


Dive into the research topics of 'Current therapy of the pemphigus group'. Together they form a unique fingerprint.

Cite this